Publication

1995 - Oxford University Press, New York, New York (State)

Language

English

Word Count

67,000 words, Guess

Page Count

268 pages

Identifiers

and 4 more

Classifications

  • DDC174/.2
  • LCCRM340 .B76 1995
  • LCCRM340.B76 1995

Description

Although most developed countries have extensive regulations governing the testing, approval and marketing of new drugs, there are major gaps in these regulations. In this compelling new volume, Dr. Brody uses the example of the development of thrombolytic drugs to identify several such gaps. Issues addressed include the use of placebo control groups in clinical trials, the importance of determining the type of consent that should be obtained for emergency research, and ways to avoid conflicts of interest in clinical trials. He also discusses topics such as deciding to continue clinical trials or to approve a drug quickly, maintaining a proper balance between efficacy and safety in drug approval, the pricing of new drugs and considering prices when ordering drugs. This work offers the first comprehensive analysis from an ethical perspective of the entire drug development process, and it does so while comparing American and European approaches to the process.

Subjects

Other Editions

  • Ethical issues in drug testing, approval, and pricing: the clot-dissolving drugsOxford University Press1995-01-01

Similar Books

Reader Reviews

No reviews yet for this book.

Be the first to share your thoughts!